

***Fiscal Year 2023 Department of Defense Tuberos Sclerosis Complex Research Program
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Exploration – Hypothesis Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT9425-23-TSCR-P-EHDA</p>	<p>Investigators at all academic levels (or equivalent), including postdoctoral fellows</p>	<ul style="list-style-type: none"> • Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the tuberous sclerosis complex (TSC) research field. • Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.104(d) or eligible for expedited review under 21 CFR 56.110. • <i>Preliminary data not required.</i> • <i>Clinical trials not allowed.</i> 	<ul style="list-style-type: none"> • The maximum period of performance is 2 years. • The maximum allowable funding for the entire period of performance is \$150,000 in direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. 	<p>Pre-Application (Letter of Intent): June 8, 2023 5:00 p.m. Eastern time (ET)</p> <p>Application: July 7, 2023 11:59 p.m. ET</p>
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT9425-23-TSCR-P-IDA</p>	<p><i>Established Investigators:</i></p> <p>Independent investigators at or above the level of Assistant Professor (or equivalent)</p> <p><i>or</i></p> <p><i>New-to-the-Field Investigator:</i></p> <p>Independent investigators at or below the level of Assistant Professor (or equivalent) or Established Investigators in an area other than TSC at or above the level of Assistant Professor seeking to transition to a career in TSC</p>	<ul style="list-style-type: none"> • Promotes ideas that have the potential to yield high-impact findings and new avenues of investigation. • <i>Preliminary data expected.</i> • <i>Clinical trials not allowed.</i> • <i>New-to-the-Field Investigator Option</i> supports the continued development of promising independent investigators that are early in their faculty appointments and/or the transition of established investigators from other research fields into a career in the field of TSC research. • Applications from New-to-the-Field Investigators and Established Investigators will compete separately. 	<ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding for the entire period of performance is \$500,000 in direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. 	<p>Pre-Application (Letter of Intent): June 8, 2023 5:00 p.m. Eastern time (ET)</p> <p>Application: July 7, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Translational Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT9425-23-TSCRP-CTRA</p>	<p>Independent Investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> • Supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including, diagnosis, prognosis, or treatment of TSC. • Applications may include correlative studies that are associated with a completed clinical trial. • Supports studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of pharmacokinetics/ pharmacodynamics. • Applications may include a small pilot clinical trial intended to inform the next step in the continuum of translational research. • Preclinical studies may be appropriate but must include a clinical component. • Projects that are exploratory and/or strictly animal research will not be considered for funding. • <i>Partnering PI Option available.</i> • <i>Collaborations between clinicians, research scientists, and/or institutions are strongly encouraged.</i> • <i>Preliminary data required.</i> 	<ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding for the entire period of performance is \$1,000,000 in direct costs. • The maximum allowable funding for the entire period of performance is \$1,150,000 in direct costs for applications including a Partnering PI Option. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	<p>Pre-Application (Letter of Intent): June 8, 2023 5:00 p.m. Eastern time (ET)</p> <p>Application: July 7, 2023 11:59 p.m. ET</p>